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PMP22 related neuropathies comprise (1) PMP22 duplications leading to Charcot-Marie-Tooth disease type 1A
(CMT1A), (2) PMP22 deletions, leading to Hereditary Neuropathy with liability to Pressure Palsies (HNPP), and (3)
PMP22 point mutations, causing both phenotypes. Overall prevalence of CMT is usually reported as 1:2,500,
epidemiological studies show that 20-64% of CMT patients carry the PMP22 duplication. The prevalence of HNPP
is not well known. CMT1A usually presents in the first two decades with difficulty walking or running. Distal
symmetrical muscle weakness and wasting and sensory loss is present, legs more frequently and more severely
affected than arms. HNPP typically leads to episodic, painless, recurrent, focal motor and sensory peripheral
neuropathy, preceded by minor compression on the affected nerve. Electrophysiological evaluation is needed to
determine whether the polyneuropathy is demyelinating. Sonography of the nerves can be useful. Diagnosis is
confirmed by finding respectively a PMP22 duplication, deletion or point mutation. Differential diagnosis includes
other inherited neuropathies, and acquired polyneuropathies. The mode of inheritance is autosomal dominant and
de novo mutations occur. Offspring of patients have a chance of 50% to inherit the mutation from their affected
parent. Prenatal testing is possible; requests for prenatal testing are not common. Treatment is currently symptomatic
and may include management by a rehabilitation physician, physiotherapist, occupational therapist and orthopaedic
surgeon. Adult CMT1A patients show slow clinical progression of disease, which seems to reflect a process of normal
ageing. Life expectancy is normal.
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PMP22 related neuropathies can be divided in three
groups. The first group is caused by a PMP22 duplica-
tion, and constitutes the majority of Charcot-Marie-
Tooth disease type 1A (CMT1A). The second group
is caused by a PMP22 deletion, leading to Hereditary
Neuropathy with liability to Pressure Palsies (HNPP).
The third group is composed of neuropathies related to
point mutations in the PMP22 gene and is classified as
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type 1A (CMT1A)
Disease name
Charcot-Marie-Tooth disease type 1A (CMT1A). Synonyms:
Hereditary Motor and Sensory Neuropathy type Ia
(HMSN Ia). Orphanumber ORPHA101081.Definition
Charcot-Marie-Tooth disease (CMT), also known as
Hereditary Motor and Sensory Neuropathy (HMSN) [1],
encompasses a clinically and genetically heterogeneous
group of disorders characterized by predominantly distal
muscle weakness and atrophy, and sensory loss. Thentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in France and independently by Tooth in Great Britain
and was named after them [2,3]. CMT is the commonest
inherited neuromuscular disorder. More than 45 causa-
tive genes have been identified [4,5]. Despite the genetic
heterogeneity, the clinical phenotype is relatively homo-
geneous [6]. Classification is based on a combination of
neurophysiologic characteristics, inheritance pattern,
and underlying genetic cause [7]. Based on neurophysio-
logic findings three different subtypes are distinguished,
i.e. the demyelinating type (CMT1) defined by a motor
conduction velocity (MCV) of the median or ulnar nerve
of less than 38 m/s, the axonal type (CMT2) with MCV
above 38 m/s [8], and an intermediate type [9,10]. The
existence of the latter is a controversial topic. Several
definitions exist for the term “intermediate”. It has been
used in individuals with a MCV between 30 and 40 m/s
[10,11], in individuals with clinical and histopatho-
logical evidence of both abnormal myelin and axon ab-
normalities [11,12] and in families in which members
have either a demyelinating phenotype or an axonal
phenotype, like families with X-linked CMT due to
GJB1-mutations, with male members showing a demye-
linating type and female an axonal type [9,13]. CMT
can be inherited in an autosomal dominant, autosomal
recessive and X-linked manner. Previously, histopatho-
logical features were also applied to distinguish demyelin-
ating from axonal neuropathy [1,14]. However, nowadays,
a nerve biopsy for diagnosis is considered to be obsolete.
Further subclassification is based on the underlying gen-
etic cause. CMT1A is the most common subtype of
CMT1. This autosomal dominantly inherited demyelinat-
ing form of CMT is caused by a 1.5 Mb duplication on
chromosome 17p11.2 [15,16], containing the gene coding
for peripheral myelin protein 22 (PMP22) and thus lead-
ing to three copies of the PMP22 gene [17-20].
Epidemiology
Overall prevalence of CMT is usually reported as
1:2,500 [21]. Several more recent epidemiological stud-
ies [22-25] reported prevalences of CMT ranging from
1:1,214 (in Norway) to 1:6,500 (in the United Kingdom).
Epidemiological studies show that 19.6% to 64.7% of CMT
patients carry the PMP22 duplication [22,25], which gives
calculated prevalences of CMT1A in the range of 1:3,800
to 1:12,500.
Clinical description
The age of onset of CMT1A is mainly in the first two
decades [26,27] and most frequently in the first 10 years
of life [26-30]. Exceptions occur as onset at birth as a
floppy infant [28] or with congenital foot deformities
[26,31]. Late onset at 76 years [27] is mentioned and a
case report describing siblings diagnosed at age 69 and65 years [32]. CMT1A usually presents as the “classical
CMT” phenotype [7,26]. The typical presenting symp-
tom is difficulty walking or running, due to weakness of
the distal leg muscles [26,28,33]. CMT patients usually
have distal symmetrical muscle weakness and wasting,
legs (“stork appearance”) more frequently and more se-
verely affected than arms. Calf hypertrophy instead of at-
rophy may also be found [26,28,29]. Proximal weakness
can be observed in up to 28% in knee extensors
[27-29,34,35]. Foot deformity, usually pes cavus with
hammertoes, is a cardinal feature in CMT1A patients,
with up to 90% of patients presenting with pes cavus
[29]. In about one third of patients this can be the pre-
senting symptom [26]. Clawing of the hands may occur,
but is usually milder. Skeletal deformity of the spine
(scoliosis) is reported in 4-35% of patients [26-29].
Upper extremity symptoms include muscle weakness,
primarily of intrinsic muscles, and atrophy. Decreased
manual dexterity was found to be a common finding
among subjects with CMT1A [36]. Sensory symptoms
are usually less prominent and can be subtle [8,26,37,38].
Impaired sensation is usually found in a stocking-glove
distribution with the legs more frequently and more se-
verely affected than the arms. Large fibre sensory involve-
ment leads to proprioceptive loss, causing balance
difficulties [37]. Small fibre sensory loss can be present
with complaints of cold feet and decreased temperature
discrimination sense [37]. Pain in CMT patients is more
common than previously recognized, with 55-70% of
CMT1A patients reporting pain [39,40], which is con-
sidered predominantly nociceptive. Severe fatigue is re-
ported in 60% of adult patients [41] and is also reported in
children (24%, in contrast to 14% of general school-based
population) [42]. Tremor, especially of the hands, can be a
feature [26-29,37]. In some cases the tremor can be quite
severe. Several CMT1A patients with tremor are described
as having a Roussy-Lévy phenotype [26,43,44]. However,
the original Roussy-Lévy family carried a mutation in the
MPZ gene [45]. Nonprogressive sensorineural hearing im-
pairment is described in CMT1A patients [46]. Sixty-one
percent of the paediatric CMT1 patients (16/18 with
PMP22 duplication) showed significantly impaired speech
perception ability, although they showed normal or near-
normal sound detection [47]. Vestibular impairment
seems to be frequent in patients with CMT [48]. Phrenic
nerve involvement, causing dyspnoea when lying flat or
nocturnal hypoventilation, is infrequent in CMT1A, but
has been reported in some, severely affected, patients (in
5% [26] and 3.5% [28], respectively). CMT may predispose
to obstructive sleep apnoea [49]. Only rarely patients have
normal reflexes, mostly they are absent (in up to 46-75%
of patients) or depressed [26-29]. Hypertrophy of nerves is
a feature of CMT1A, rarely clinically present and mostly
established by pathology [44] or imaging studies [50-53].
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even within the same family [54,55]. Overall, 1-7% of pa-
tients become wheelchair dependent [27,28,35]. A walk-
ing aid (cane, crutches or walker) is needed by 3-14% of
patients [27,28,35,38]. Dejerine-Sottas syndrome (in the
past also known as Hereditary Motor and Sensory Neur-
opathy type III) is a hereditary neuropathy with early
onset and severe presentation. Currently it is not con-
sidered a different entity, but part of the phenotypic
spectrum of CMT1, because the underlying genetic de-
fects are known CMT1 genes, like the PMP22 duplica-
tion [56,57]. There are case reports on severely affected
CMT patients demonstrating the presence of two muta-
tions in two different CMT-related genes (“double
trouble”) [58,59]. On the other side of the spectrum, pa-
tients can be asymptomatic (1.6% to 17% [26-28]) or
only exhibit mild symptoms, like foot deformity, leading
to no or only mild problems with walking [26,27]. How-
ever the term asymptomatic is questionable, as asymp-
tomatic individuals might not experience complaints but
clinical examination may show pes cavus and/or ankle
jerk areflexia [27].
Although always considered a disease affecting the per-
ipheral nervous system, a recent report on 15 CMT1A
patients described central nervous system involvement
[60]. Decreased white matter volume was found in 73%,
with minimal, predominantly executive, cognitive disor-
ders in 77%.
Electrophysiologically, CMT1A is characterized by a
homogeneous and diffuse motor and sensory nerve con-
duction slowing [6,27,38,54,61,62]. Due to a combined
effect of dysmyelination and axonal dysfunction and loss,
sensory nerve action potentials (SNAP) are also fre-
quently reduced in the arms and reduced to absent in
the legs [27,29,38].
Nerve biopsies show decreased density of myelinated
nerve fibres, most pronounced in biopsies taken in the first
year of life. The mean g-ratio (axon diameter versus fibre
diameter) is significantly lower than normal [63]. Charac-
teristic onion bulb formation occurs after the age of six
[44,63-65]. Axonal loss is also found in childhood [65].
Abnormal myelination probably extends over the whole
nerve length. The most severe pathological changes were
seen distally in nerves, but there were also changes in
the proximal nerves and in the roots [66].
An overview of the key features of CMT1A is presented
in Table 1.
Aetiology
CMT1A is predominantly caused by a 1.5 Mb duplica-
tion on chromosome 17p11.2 [15,16] that includes the
PMP22 gene [17-20]. Cases of CMT1A with different
sized duplications, most including the PMP22 gene
[67,68] or a copy number variant upstream of PMP22are reported [69]. Occasionally (<5%) point mutations in
the gene are found (see “PMP22 point mutations”). Mu-
tations in the PMP22 gene had previously been identi-
fied as the Trembler mouse mutation. Identification of
an identical mutation in a CMT family showed that the
PMP22 gene is also responsible for CMT1A [70].
Gene dosage of PMP22 is the proposed mechanism,
supported by the finding that increased PMP22 protein
[71] and elevated PMP22 messenger RNA (mRNA) was
found in CMT1A patients in sural nerve biopsies [72].
The PMP22 gene encodes a 22-kD protein that com-
prises 2 to 5% of peripheral nervous system myelin.
PMP22 is produced primarily by Schwann cells. It is
expressed in the compact portion of essentially all mye-
linated fibres in the peripheral nervous system [73]. The
exact function of PMP22 is still not elucidated. Studies
in injured nerve suggested a role during Schwann cell
growth and differentiation [73].
CMT1A has been considered a primary demyelinating
neuropathy, as also shown by low conduction velocities
on electrophysiology in CMT1A patients. However, it
has become clear that axonal dysfunction determines
clinical disease severity [35,38,74,75]. Onion bulbs seen
on morphological studies of nerve biopsies are a sign of
de- and remyelination. Evidence is accumulating that
CMT1A might be a disorder of dysmyelination instead
of demyelination, meaning myelination is delayed and
normal myelination is never reached [76-79].
Diagnosis (diagnostic criteria and algorithms) and
diagnostic methods
If a patient presents with a chronic motor and sensory
polyneuropathy, CMT should be one of the differential
diagnoses. In the assessment of any patient with a poly-
neuropathy, the first issue to consider is whether the poly-
neuropathy is hereditary, by taking a detailed family history
about polyneuropathies, walking difficulties or pes cavus.
The mode of inheritance is autosomal dominant, but one
should be aware of asymptomatic or non-diagnosed family
members and a de novo rate of 10% [80,81].
Electrophysiologic evaluation is needed to determine
whether the polyneuropathy is demyelinating, axonal or
intermediate. Sonography of median nerves can be help-
ful. It was shown that median nerve cross-sectional area
(CSA) was significantly increased in CMT1A compared
to CMT2 [50,52,53], and CSA correlated with nerve
conduction slowing in CMT1A [52].
In autosomal dominantly inherited uniformly demye-
linating sensorimotor polyneuropathy, the PMP22 dupli-
cation, the most common cause of CMT1, is tested first.
In severe cases “double trouble” (the presence of two
mutations in two different CMT-related genes) can be
present. Currently, with the knowledge and easy accessi-
bility of DNA diagnostics, nerve biopsy is obsolete.
Table 1 Key features of CMT1A and HNPP
CMT1A HNPP
Duplication of PMP22 Deletion of PMP22
Clinical features Age of onset mainly in first two decades Painless attacks of numbness, muscular weakness,
and atrophy, recurrent and focal
Presenting symptom is difficulty walking or running
Preceded by minor compression on nerve
Distal symmetrical muscle weakness and wasting,
legs > arms Age at onset mostly in the second or third decade
Pes cavus very frequent Pes cavus found in 4-47% of patients
Sensory symptoms (stocking-glove distribution) usually
less prominent, legs > arms
Full recovery in 50% of episodes, usually in days
to weeks
Pain more common than previously recognized Sequelae rarely severe
Large intrafamilial clinical variabilityReflexes absent or depressed
Large clinical variability between patients, even within family
Electrophysiological
features
Homogeneous and diffuse MCV and SCV slowing Increase in distal motor latencies, especially of median
and peroneal nerve
CMAP amplitudes reduced, especially distally in the legs
Focal motor slowing at entrapment sites
SNAP amplitudes frequently reduced to absent
MCV normal to slightly reduced in other segments
SCV decreased and SNAP amplitudes often reduced
Neuropathological
features
Abnormal myelination over the whole nerve length Segmental de-and remyelination
Onion bulbs Tomacula pathologic hallmark, but not pathognomonic
Decreased density of myelinated nerve fibres Variable large-fibre loss
CMAP = compound muscle action potential. MCV = motor conduction velocity. SCV = sensory conduction velocity. SNAP = sensory nerve action potentials.
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Also in a patient without a positive autosomal dominant
family history presenting with a uniformly demyelinating
sensorimotor polyneuropathy, CMT1A should be consid-
ered and tested first. If DNA-testing for the PMP22 dupli-
cation is negative, other forms of CMT1 should be
considered. An algorithm for genetic testing of patients
with demyelinating polyneuropathy is presented in Figure 1.
In view of the large number of genes involved in CMT, a
gene by gene analysis is time consuming. With the intro-
duction of Next Generation Sequencing (NGS) in clinical
diagnostics the development of NGS panels for CMT is
expected [82-84]. The first diagnostic step in patients
with demyelinating polyneuropathy should remain test-
ing for PMP22 duplication. If negative, all the genes
should be sequenced in one run (panel). Whole exome
sequencing (WES) is not recommended as a first screen
since the costs are still high and the sensitivity of this
technology is not yet high enough. WES should only be
applied to those familial cases where screening of the af-
fected family members has proven negative. The results of
the NGS panel should be discussed with geneticists with
expertise in the CMT-area. Key issue in the analysis is the
likelihood of the sequence variant to be pathogenic and to
correspond with the patient’s phenotype and inheritance
pattern. This incorporates cosegregation analysis in af-
fected family members. If technical resources or expertise
for NGS is not available, a candidate gene approach is also
presented in Figure 1.Demyelinating polyneuropathy can also be a sign of
autosomal recessive metachromatic leucodystrophy [85],
Refsum’s disease [86], Krabbe’s disease [87], X-linked adre-
nomyeloneuropathy [88], Pelizaeus-Merzbacher syndrome
[89] and Lowe syndrome [90], but in addition other char-
acteristic symptoms and signs will be present. Acquired
causes associated with segmental demyelinating neur-
opathy, e.g. diabetes mellitus, and chronic inflammatory
demyelinating polyneuropathy (CIDP) should also be con-
sidered. Typically, CIDP shows a subacute or fluctuating
course, multi-focal demyelinating features on electrophysi-
ology, high protein levels in cerebrospinal fluid, no pes
cavus and a negative family history [91,92]. However, in
clinical practice, symptoms of CIDP and CMT can overlap
[93]. Establishing the diagnosis is important, since CIDP is
treatable. Diabetes mellitus is the most common cause of
neuropathy [94] and should always be considered in a
polyneuropathy patient. A distal symmetrical sensory poly-
neuropathy is the most common pattern of diabetic neur-
opathy [95]. Diabetic neuropathy is usually axonal, but can
also show demyelinating features on electrophysiology
[91]. As opposed to CMT, diabetic neuropathy has pre-
dominantly sensory and autonomic manifestations [94].
Genetic counselling and antenatal diagnosis
CMT1A is inherited in an autosomal dominant fashion.
Thus offspring of CMT1A patients have a chance of 50%
to inherit the PMP22 duplication from their affected
parent. Anticipation is described in several case studies
Figure 1 (See legend on next page.)
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Figure 1 Algorithm for genetic testing of patients with demyelinating neuropathy. Analysis should always start with testing for PMP22
duplication. If negative, a panel containing genes associated with CMT1 should be tested if technical recourses and expertise for Next Generation
Sequencing (NGS) is available, otherwise targeted gene analysis as depicted on the right is the next step. When no pathogenic mutation is
identified, Whole Exome Sequencing should be considered in familial cases only.
van Paassen et al. Orphanet Journal of Rare Diseases 2014, 9:38 Page 6 of 15
http://www.ojrd.com/content/9/1/38[96-98]. However, in our opinion this rather reflects
phenotypic variability within a family, which is a well
known phenomenon in CMT1A [54,55]. The variability
is likely, at least in part, due to genetic modifiers (see
section “unresolved questions”).
When the diagnosis of an inherited condition is made
in a family, issues like family planning and testing of rel-
atives at risk can arise. The best way of handling these
issues, is nondirective counselling. This is based on the
autonomy of the patient to make the decision that serves
his/her best interests, after receiving nondirective infor-
mation about benefits and disadvantages of testing,
considering for instance family planning, work related
choices and insurance issues. If clinically unaffected fam-
ily members request predictive testing and are found to
carry the PMP22 duplication, it is likely that they will
develop some features, since the penetrance of the dis-
ease is nearly 100% [99]. There is consensus about not
testing minors at risk of an inherited disorder without
treatment or preventive options, because of the chance
of psychological harm to the child [100,101]. Prenatal
testing on foetal DNA is possible. During pregnancy
foetal DNA can be obtained by chorionic villus sampling
or by amniocentesis, both with a risk of miscarriage due
to the sampling. Requests for prenatal testing for condi-
tions that do not affect life span or intellect are not com-
mon. Requests for prenatal testing should be managed
in a multidisciplinary team, involving genetic counsel-
lors, psychologists and (paediatric) neurologists [102].
Pre-implantation Genetic Diagnosis (PGD) is a tech-
nique used to identify genetic defects in embryos created
through in vitro fertilization before pregnancy. PGD is
sparsely undertaken for CMT1A [103]. In some coun-
tries it is not considered an indication for PGD [104].
Management including treatment
Treatment consists of supportive care and may include
management by a rehabilitation physician, physiotherap-
ist, occupational therapist and orthopaedic surgeon.
Supportive care for the legs includes exercise training,
shoe inlays, orthopaedic shoes and orthoses. In case of se-
vere skeletal deformities surgical correction may be con-
sidered. However, evidence is limited; a Cochrane review
concluded that methodologically sound trials are required
for any of these physical interventions [105,106]. Ortho-
paedic surgery to correct severe pes cavus or hammertoes
may be helpful [107-109]. Likewise, robust evidence is not
present. Symptomatic treatment for the arms has not beenstudied extensively. Wearing a thumb opposition splint
may improve manual dexterity in CMT [110]. Tendon
transfer surgery is moving a tendon from its original at-
tachment to a new one to restore the action of the trans-
ferred muscle and improve function. It may improve
thumb opposition of patients with CMT [111,112]. Symp-
tomatic drug treatment for positive sensory symptoms
and for muscle cramps may be useful, but has not been in-
vestigated specifically for CMT.
Co-existence of diabetes mellitus in a CMT1A patient
is described to exacerbate symptoms of the peripheral
neuropathy [113,114], and therefore optimal control of
blood sugar should be strived for in a CMT patient with
diabetes. Toxin or medication-induced worsening of
pre-existing peripheral neuropathy is a generally known
phenomenon [115]. The use of neurotoxic agents, espe-
cially vincristine, can have a devastating effect, even in
low dose [116,117] and should be avoided in patients
with CMT.
Perspectives on future therapeutic developments are
discussed in the “unresolved questions” section.
Prognosis
As mentioned, axonal dysfunction determines clinical
disease severity [35,38,74,75]. Nerve conduction veloci-
ties are found to remain stable in children after the
age of six years [35,77,118,119]. There are only a few
natural history studies done in adult CMT1A patients
[35,118,120], all showing slow clinical progression. Only
one 5-year natural history study included age-matched
controls [35] and showed that baseline strength and
compound muscle action potential (CMAP) amplitudes
were lower in patients than in controls, while adult
CMT1A patients and controls had a similar decline of
strength and of CMAP amplitudes over time, suggesting
that progression in patients may reflect a process of nor-
mal ageing. Physical disability however increased over
time in the patient group and not in the control group.
This may be explained by fewer reserves in patients, as
baseline strength and CMAP amplitudes were lower.
Also skeletal deformations may progress. Studies about
the natural history in children are ongoing. Life expect-
ancy is normal.
Unresolved questions
Why an increase or decrease in PMP22 gene copy num-
ber results in CMT1A or HNPP is still unknown.
PMP22, also known as growth arrested specific gene 3
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increases upon growth arrest [121] and in proliferating
cells the levels are very low. The highest expression of
PMP22 is detected in the Schwann cells of compact
myelin. It is possible, that in these cells PMP22 serves
another function. There is no unifying hypothesis how a
PMP22 copy number variation or mutation leads to dis-
ease. In case of point mutations a toxic effect of mis-
folded protein is suggested, but this does not hold for
the duplication and deletion of a normal copy of PMP22.
In that case one can speculate that PMP22 interacts with
other myelin components and stoichiometry is essential
for proper function. However, there is no experimental
data for this hypothesis.
The variability of the CMT1A phenotype, even within
families [27], suggests the presence of modifiers - genetic
and/or external factors - but these have not been identi-
fied thus far. We expect that part of the variation of the
phenotype is due to genetic factors. Severely affected
“double trouble” cases (the presence of two mutations in
two different CMT-related genes) are reported [58,59]
and show that known CMT genes can act as modifiers.
Systematic screening of CMT genes in large cohorts of
patients is necessary to identify the more common vari-
ants that affect the phenotype. With targeted NGS or
whole exome sequencing [122] probably becoming the
standard in DNA diagnostics in the near future, it is
expected that variants in CMT related genes will be
identified, which, together with a pathogenic mutation,
determine the phenotypic expression of CMT in an indi-
vidual patient. Thus far, the number of reports on these
double trouble cases is low. We recommend that DNA
screening of other CMT genes is performed in severely
affected patients carrying a PMP22 duplication.
Variation in pathways involved in the immune system
and its effect on nerve degeneration or regeneration may
also affect the severity of the CMT phenotype. Analysis
of transgenic models for CMT have excluded a role for
B- and T-cells in the PMP22 overexpressing mice [123].
However, alterations in the innate immune system can
affect the severity of the neuropathy. Heterozygous dele-
tion of monocyte chemoattractant protein-1 (MCP-1)
does affect axonal properties [124] and it was shown that
inhibition of the complement system has a major effect
on nerve degeneration and regeneration [125,126].
Therapy for CMT1A thus far consists of supportive care
only. Since the CMT1A phenotype is shown to result from
a gene dosage effect [17-19], it is hypothesized that regulat-
ing the PMP22 gene dosage may be a therapeutic target.
Two compounds that have been found to regulate PMP22
mRNA levels in rodent models are progesterone [127,128]
and ascorbic acid [129]. Ascorbic acid did not show a
beneficial effect in several randomised controlled trials
[130-134]. Onapristone, a progesterone receptor antagonist,reduced PMP22 mRNA levels and improved the phenotype
in rodents [127]. However, clinical trials were not initiated
due to the known serious side effects in humans [135]. No
reports about progesterone antagonist treatment in CMT
have been published since.
A pilot study undertaken by Sahenk et al. [136] showed
that neurotrophin-3 (NT-3) improved the phenotype of
the Trembler-J mouse and also led to slight improve-
ment of sensory and reflex scores in CMT1A patients.
Sahenk and colleagues proposed NT-3 treatment via
adeno-associated virus (AAV) delivery to muscle and
they showed in the Trembler-J mouse model that rAAV1.
NT-3 therapy resulted in measurable NT-3 secretion
levels in blood and improvement in motor function,
histopathology, and electrophysiology of the peripheral
nerves [137].
Cell line assays for high-throughput screens are a
valuable new tool to select candidates from large num-
bers of existing compounds. Regulatory elements in the
PMP22 gene are found that direct expression of PMP22
[138,139]. An intronic regulatory element was coupled
to the luciferase gene, creating a high-throughput
screen platform [140]. A multitude of compounds were
tested on this assay, resulting in the identification of
four compounds that decreased PMP22 mRNA and
protein [140]. Follow-up assays followed by animal tri-
als are the next step.
Two transgenic rodent models, the C3-PMP mice and
the CMT-rat closely resemble human CMT1A and may
be appropriate models for therapeutic studies [79,141].
An important issue in developing treatment with drugs
that showed benefit in animal studies is when to proceed
to trials in patients. It can be argued that positive results
in animal studies should be replicated first, before clin-
ical trials in patients are developed [142].
Effective drug treatment may be directed at normal-
ization of the myelination process, although improve-
ment of the axonal function should be the ultimate goal.
In view of this, therapies modulating the innate immune
response should not be neglected. Since axonal degener-
ation already starts in childhood, drug treatment begin-
ning early in life is expected to be most beneficial.
PMP22 deletion - Hereditary Neuropathy with
liability to Pressure Palsies (HNPP)
Disease name
Hereditary Neuropathy with liability to Pressure
Palsies (HNPP). Synonymes: tomaculous neuropathy.
Polyneuropathy, familial recurrent. Orphanumber
ORPHA640.
Definition
A deletion of the 1.5 Mb region on chromosome
17p11.2, the same region that is duplicated in CMT1A
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order Hereditary Neuropathy with liability to Pressure
Palsies (HNPP). HNPP is an episodic, multifocal neur-
opathy. The typical clinical presentation is that of recur-
rent transient pressure palsies without pain, but with
focal motor and sensory symptoms in the territory of a
single nerve or the brachial plexus [144].
Epidemiology
The prevalence of HNPP is not well known [37]. Preva-
lences of 7.3 per 100,000 [23] to 16 per 100,000 [145]
are reported.
Clinical description
HNPP typically leads to episodic, painless, recurrent,
focal motor and sensory peripheral neuropathy [33]. It
may cause attacks of numbness, muscular weakness, and
atrophy [146]. Many episodes are preceded by minor
compression on the affected nerve [146], for instance
prolonged positioning of the limb. The most vulnerable
nerves are the peroneal and ulnar nerves (30-48% and
21-28%, respectively), followed by the brachial plexus
(12-27%), radial nerve (4-13%) and median nerve (4-11%)
[144,147,148].
Age at onset of first HNPP symptoms is mostly in
the second or third decade, with a large range from
birth (although only two cases are described, one with
an transient Erb’s paresis [145] and one with neur-
opathy of the peroneal nerve and pes cavus [149]) to
the eighth decade [144,145,148,150-153]. Most patients
(60-70%) present with a single, focal, acute neuropathy
[144,148,150]. Cranial nerves are affected rarely [154].
Transient palsies of the facial [155-157], trigeminal
[155,158], hypoglossal [155,159] and recurrent nerve
[160] have been described. Although not being a typ-
ical transient nerve palsy, sensorineural hearing im-
pairment of postnatal onset with progression beyond
presbyacusis has been reported [46]. Other uncommon
presentations include recurrent short-term positional
sensory symptoms, progressive sensorimotor mononeuro-
pathy of the peroneal nerve, chronic sensory polyneuro-
pathy, chronic sensorimotor polyneuropathy and subacute
peripheral quadriparetic episodes (initial diagnosis was
chronic idiopathic demyelinating polyneuropathy) [144].
Also a Davidenkow phenotype (scapuloperoneal syn-
drome) is described [161].
On clinical examination, besides muscle weakness, at-
rophy and/or sensory signs in the affected nerves, re-
duced or absent tendon reflexes, mostly the ankle jerks,
can be noted [144,154]. Pes cavus may be found in
4-47% [144,148,150-152,157]. The symptoms from acute
neuropathy usually disappear in days to weeks [146]. Full
recovery occurs in 50% of episodes. Remaining symp-
toms are rarely severe [162]. Chronic motor deficits afternerve palsies are noted in 10% to 15% [144,148,150].
Other chronic symptoms like cramps, paresthesias and
exercise-induced myalgia have been described [150].
There is large clinical variability between HNPP patients.
At the mild end of the spectrum, patients can be clinically
asymptomatic. In different studies the percentages of
asymptomatic family members of index patients varied
from 6% to 23% [144,148,150,152,153]. At the severe end of
the spectrum patients have residual symptoms after nerve
palsies, which can mimic a CMT phenotype [146,163].
Electrophysiological studies show a characteristic pat-
tern [144,147,164-167]. Essentially all HNPP patients,
whether symptomatic or not [164] show an increase in
distal motor latencies, especially of the median and
peroneal nerves [166]. Most patients show focal motor
slowing at entrapment sites, more commonly in the
ulnar nerve at the elbow than in the peroneal nerve at
the fibular head [144,147,164,166]. In other segments,
MCV is normal in most cases, but can be slightly re-
duced in some. Sensory nerve conduction velocities are
often decreased and sensory nerve action potential am-
plitudes are often reduced [166,167].
Nerve biopsy shows segmental de- and remyelination
and varying large-fibre loss [168]. Tomacula, which are
massive redundancies or overfolding of layers of variable
thickness in the myelin sheath, are the pathologic hall-
mark [33], but are not pathognomonic.
Central nervous system white matter lesions have been
reported in isolated patients and in several members of a
large family with HNPP [169-171]. A recent report on
15 HNPP patients described central nervous system in-
volvement [60]. Decreased white matter volume was
found in 71%, with minimal, predominantly executive,
cognitive disorders in 64%.
An overview of the key features of HNPP is presented
in Table 1.
Aetiology
A 1.5 Mb deletion on chromosome 17p11.2 [143,154] is
found in approximately 85-90% of patients with clinical
evidence of HNPP. Most of the CMT1A- or HNPP-
associated rearrangements in 17p11.2 are recurrent and
mediated by nonallelic homologous recombination, al-
though rare cases of HNPP have deletions of different
size but always including the PMP22 gene [68]. HNPP is
an autosomal dominant disease. The de novo rate is
probably 20% [164]. Rare cases have mutations in the
PMP22 gene. These mutations often result in stop co-
dons and thus give rise to a null allele [172].
The gene dosage hypothesis is supported by the find-
ing of decreased PMP22 protein [71] and decreased
PMP22 mRNA expression levels in HNPP patients [173]
that correlated with phenotype [174]. It is hypothesized
that the focal symptoms of HNPP are caused by
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of CMAP amplitudes between distal and proximal sites
of stimulation) [152]. Structural abnormalities at the
node of Ranvier explain the changes in axonal excitabil-
ity, and these abnormalities would predispose the nerves
to conduction block when subjected to pressure or stretch
[175]. In a mouse model heterozygous for Pmp22, con-
duction block was more rapidly induced by mechanical
compression on the nerve in comparison to normal
nerves [176] and recovery was slower. They found focal
axonal constrictions within tomacula. Reduced axonal
diameter raises resistance to action potential propagation
and thus predisposes these axons to conduction block.
When the nerve is compressed, it may cause even further
thinning of axons.
Diagnosis (diagnostic criteria and algorithms) and
diagnostic methods
Guidelines for diagnosis of HNPP are proposed by
Dubourg et al. [154]. A clinical manifestation of acute,
painless, recurrent peripheral nerve palsies is typical
for HNPP. However, also with more uncommon pre-
sentations (see “clinical description”) HNPP should be
considered. A family history consistent with autosomal
dominant inheritance is often present, but is not a
prerequisite considering the de novo rate of 20% and
asymptomatic occurrence of the disease. Electrophysi-
ology of HNPP patients helps in establishing the diag-
nosis. Sonography of nerves show nerve hypertrophy
at entrapment sites [177,178], although not always
significant [52].
If HNPP is suspected, DNA testing for the deletion of
the PMP22 gene, followed by sequencing of the PMP22
gene if no deletion is found, can confirm the diagnosis.
Like in CMT1A, nerve biopsy is essentially obsolete.
Differential diagnosis
Pressure palsies are commonly the result of acquired
physical compression of peripheral nerves, mostly of the
median nerve at the wrist (carpal tunnel syndrome), the
peroneal nerve at the fibular head and the ulnar nerve at
the elbow [162]. Screening for HNPP in 50 patients with
isolated carpal tunnel syndrome showed that none of the
patients had the PMP22 deletion [179]. The suspicion of
HNPP should be higher if a patient suffers from more
than one episode of compression neuropathy, if there is
also an unexplained polyneuropathy present and if there
is a family history of neuropathy [162]. Mononeuropa-
thies may also be caused by compression due to a
tumour, bleeding or abscess. In case of a neuropathy of
the brachial plexus with a positive family history heredi-
tary neuralgic amyotrophy (HNA) is considered most
commonly [146,163] and can be associated with muta-
tions in the SEPT9 gene [180]. The nerve palsy in HNPPis painless, whereas the brachial plexopathy in HNA is
preceded by severe pain. In case of a negative family his-
tory the sporadic form of HNA, idiopathic neuralgic
amyotrophy, should be considered [163].
Genetic counselling and antenatal diagnosis
HNPP is an autosomal dominantly inherited disorder.
For general aspects see corresponding paragraphs in
the CMT1A section. In our experience, predictive
testing, prenatal testing and PGD are not commonly
requested.
Management including treatment
Treatment is currently symptomatic. Management during
a pressure palsy may include transient bracing. If a pres-
sure palsy is not transient but residual, the bracing may
need to be permanent. Patients should be informed about
avoiding activities that are risk factors for pressure palsies.
These activities include prolonged sitting with legs
crossed, occupations requiring repetitive movements of
the wrist, prolonged leaning on elbows and rapid weight
loss [162,181]. Toxin or medication-induced worsening of
pre-existing peripheral neuropathy is a generally known
phenomenon [115]. Vincristine, used in chemotherapy,
has been reported to exacerbate HNPP [182]. No system-
atic controlled study of surgical decompression of nerves
has been done. Given the vulnerability of the peripheral
nerves in patients with HNPP, surgery is generally consid-
ered unfavourable [146].
Perspectives on future therapeutic developments are
discussed in the "unresolved questions" section.
Prognosis
No natural history studies of HNPP exist. The prognosis is
therefore unsure. In a study addressing age associated
changes in electrophysiology [152], a reduction in CMAP
with increasing age at examination was observed in nerves
vulnerable to entrapment. This nerve-specific CMAP re-
duction likely results from a history of repetitive focal com-
pression of the nerve. It is however not mentioned how
the CMAP reduction correlates with symptoms. Recovery
from acute neuropathy is often complete, although it can
take months and if chronic symptoms persist, they are usu-
ally mild. Residual symptoms after nerve palsies can resem-
ble a CMT phenotype [146,163]. Symptomatic individuals
have the frustration and disability associated with recurrent
pressure palsies [162]. Life expectancy is normal.
Unresolved questions
As for CMT1A, the phenotype is highly variable in
HNPP, suggesting the presence of modifiers - genetic
and/or external factors. So far none are identified.
Treatment is still only symptomatic. To our knowledge
no trials have been undertaken. As HNPP is caused by a
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may be a therapeutic target, as decreasing the gene dos-
age is for CMT1A [146]. Stimulation of the endogenous
PMP22 by enhancing the regulatory elements of PMP22
might be one option. Another option is to introduce an-
other copy of the PMP22 gene into the peripheral nerve
by gene therapy. An obstacle is that increasing the dos-
age of PMP22 above a certain level will cause CMT1A.
PMP22 point mutations
Point mutations in PMP22 are found in a minority of pa-
tients suspected to have CMT or HNPP and the phenotype
may vary from mild HNPP to severe CMT1 [183,184]. Clin-
ical overlap between CMT1 and HNPP is also described,
for instance in patients with the frameshift mutation
Gly94fsX222 (c.281_282insG) [148,185]. For all general is-
sues considering CMT1A and HNPP, see previous sections.
According to some classifications CMT caused by
PMP22 mutations is also called CMT1A [7], while others
consider this a separate disease entity called CMT1E
[99,184,186]. One could argue to classify CMT caused by
PMP22 point mutations as a separate entity, because the
genetic defect is different from CMT caused by PMP22
duplication. An extra argument for considering this a sep-
arate disease entity is that PMP22 point mutations can
phenotypically lead to CMT as well as HNPP or even an
overlap between the two phenotypes. In this perspective,
HNPP due to PMP22 point mutations should also be seen
as a separate entity from HNPP due to PMP22 deletion.
Several types of PMP22 point mutations are described
(missense, nonsense, frameshift and splice-site mutations
[5]). Controversy about the pathogenicity of the Thr118Met
mutation exists. It is reported as a benign polymorphism,
as an autosomal recessive inherited mutation or as an auto-
somal dominant mutation, with HNPP as phenotype [187].
Very rare autosomal recessive neuropathy (CMT4), caused
by homozygosity for point mutations in PMP22 [188,189]
has been reported.
Conclusions
PMP22 related neuropathies are the most prevalent
amongst the inherited neuropathies. Knowledge about clin-
ical presentation of CMT1A and HNPP and the expanding
possibilities of genetic testing is a prerequisite for all
neurologists and geneticists dealing with inherited
neuropathy patients. Research on therapy has so far
largely focussed on CMT1A, because of its prevalence
and the rationale of decreasing the gene dosage of
PMP22 which could potentially reverse the phenotype.
One should keep in mind that a PMP22 directed ther-
apy can not be applied to all cases of CMT. Therefore
the genetic subtyping of CMT is essential to select those
cases that might be eligible for targeted treatment strat-
egies, as soon as these treatments become available.Abbreviations
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